Connect
MJA
MJA

Biological agents as weapons 2: anthrax and plague

Michael Whitby, Tilman A Ruff, Alan C Street and Frank Fenner
Med J Aust 2002; 176 (12): 605-608.

Summary

  • Although most naturally occurring infections with anthrax and plague are cutaneous, both organisms are most likely to be deliberately disseminated in aerosolised form, resulting in severe pulmonary illness.

  • Mortality from both would be high and rapid in the absence of early and effective treatment, making swift and effective liaison between alert clinicians and public health authorities crucial to an effective response.

  • Differentiating features include mediastinal widening (anthrax) and haemoptysis (plague).

  • Doxycycline and ciprofloxacin are effective agents for prophylaxis and treatment for both diseases.

  • Medical advocacy for strengthening the Biological Weapons Convention, particularly with an enforceable protocol including verification and compliance provisions, is needed.

Please login with your free MJA account to view this article in full

  • Michael Whitby1
  • Tilman A Ruff2
  • Alan C Street3
  • Frank Fenner4

  • 1 Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD.
  • 2 GlaxoSmithKline Biologicals, Melbourne, VIC.
  • 3 Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC.
  • 4 John Curtin School of Medical Research, Australian National University, Canberra, ACT.

Correspondence: whitbym@health.qld.gov.au

  • 1. McCall B, Looke D, Crome M, et al. Sporadic human anthrax in urban Brisbane. Commun Dis Intell 1998; 22: 189-190.
  • 2. Christopher GW, Cieslak TJ, Pavlin JA, et al. Biological warfare. A historical perspective. JAMA 1997; 278: 412-417.
  • 3. World Health Organization. Health aspects of chemical and biological weapons. Geneva: WHO, 1970; 98-109.
  • 4. Working Group on Civilian Biodefense. Anthrax as a biological weapon: medical and public health management. JAMA 1999; 281: 1735-1745.
  • 5. Turnbull PC. Anthrax vaccines: past, present and future. Vaccine 1991: 9; 533-539.
  • 6. WHO plague manual: epidemiology distribution, surveillance and control. Geneva: WHO, 1999. (WHO/CDS/CSR/EDC/99.2.)
  • 7. Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. JAMA 2000; 283: 2281-2290.
  • 8. Chin J, editor. Control of communicable diseases manual. Washington DC: American Public Health Association, 2000; 381-387.
  • 9. Titball RW, Ealey S, Williamson ED, et al. Plague. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999; 734-742.
  • 10. Gould R, Connell ND. The public health effects of biological weapons. In: Levy BS, Sidel VW, editors. War and public health. New York: Oxford University Press/American Public Health Association, 1997; 98-116.
  • 11. Pearson GS. Preventing deliberate disease. Med Conflict Surv 2000; 16: 42-59.
  • 12. Kapp C. USA goes it alone again on bioweapons convention. Lancet 2001; 358: 2058.
  • 13. Beeching NJ, Dance DAB, Miller ARO, Spencer RC. Biological warfare and bioterrorism. BMJ 2002; 324: 336-339.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.